DIABEST: Individual Determinants of Postprandial Glucose Response in Type 2 Diabetes

Sponsor
Federico II University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06057246
Collaborator
(none)
144
1
1
23.6
6.1

Study Details

Study Description

Brief Summary

Postprandial glycemia (PPG) is a relevant determinant of glucose control in people with type 2 diabetes (T2D). Epidemiological and pathophysiological studies indicate that PPG is a better risk predictor for cardiovascular disease and all-cause mortality than fasting plasma glucose. Therefore, both fasting and postprandial glycemia should be targeted to achieve optimal glycemic control and, thus, prevent or reduce the risk of diabetes complications.

Post-prandial glucose response (PGR) cannot be predicted based solely on the meals' carbohydrate content. Recent research using continuous glucose monitoring (CGM) systems has identified different patterns of PGR to a standard meal among both healthy people and individuals with type 1 diabetes. Different contributors to the PGR have emerged, including genotype, hormonal and metabolic factors, phenotype, gut microbiota composition, background diet, sleep habits, physical activity levels.

The present project aims at exploring the PGR in a real-life setting in a cohort of people with T2D, and identifying person-specific factors associated with different postprandial glucose patterns.

To this purpose, 144 individuals with T2D on treatment with diet alone or diet plus metformin will be characterized for their anthropometric, metabolic, and gut-microbiome features and will undergo a one-week observational period through CGM system, while properly recording their food intake, physical activity, and sleep habits. A mixed-nutrient standardized meal will be consumed at home in two occasions by each participant to investigate the intra-individual variability of the PGR. Moreover, in a subgroup of participants (n=60), divided according to anthropometric and metabolic features, hormonal and metabolic response to the standardized meal will be evaluated at the hospital, to explore the contribution of different T2D phenotypes to the PGR.

A further step will be developing a prediction algorithm of PGR based on the intra- and inter-individual factors shown to influence postprandial glucose, able to further optimize the management of T2D with precision therapeutic strategies.

Condition or Disease Intervention/Treatment Phase
  • Other: Test meal with postprandial samples
N/A

Detailed Description

The participants will undergo a 7-day observational period and acute postprandial tests with a standardized meal. Before the study initiation, all participants will undergo a screening visit for the assessment of inclusion and exclusion criteria. Participants meeting the inclusion criteria will be instructed to collect a stool sample and will be scheduled for the experimental visit (day 0). At day 0, each participant will arrive at the diabetes clinic in the morning, after a 10-hour fasting, to undergo:

  • venous blood sampling for biochemical determinations

  • anthropometrics and blood pressure measurements

  • body composition evaluation (bioimpedance analysis)

  • basal metabolic rate evaluation (indirect calorimetry)

  • administrations of questionnaires for the evaluation of lifestyle habits

  • positioning of a subcutaneous sensor for continuous glucose monitoring (CGM).

Information regarding characteristics of bowel movements in the day of stool sampling will be collected according to the Bristol stool scale.

The participants will be instructed to consume at home a mixed-nutrient meal at breakfast on the second day and on the last day of the observational period. PGR will be assessed by CGM.

Over the following 7 days, participants will undergo CGM while keeping stable their own dietary and lifestyle habits and will be asked to record the following information by using a dedicated app:

  • a 7-day food diary reporting all foods and drinks consumed, including dressing, portions by household measures (cup, spoons, etc.) or weight, and providing as much details as possible (i.e., cooking methods, brands names). Seven-day food records will be discussed with a skilled dietitian to check potential mistakes and missing information. Energy intake and dietary composition (nutrients and non-nutrients), and food groups consumption will be calculated using the MetaDieta software and the Food Composition Database for epidemiological Studies in Italy of the European Institute of Oncology;

  • any stressful event or drug assumption.

In parallel, during the 7-day observational period, data on physical activity levels and sleep habits will be collected by using an accelerometer (Actigraph medical device).

At the 8th day, a subgroup of 60 participants (20 with prevalent impairment of insulin sensitivity, 20 with prevalent impairment of insulin secretion, and 20 with prevalent visceral obesity - as determined by anthropometrics, fasting C-peptide, and plasma triglycerides) will return to the hospital and consume the same standardized meal consumed at home. Before and over 4 hours after the meal, venous blood samples will be collected at fixed time points for biochemical evaluations.

CGM data from 30 min before meal to 6 h after meal will be analyzed. Postprandial blood glucose changes will be calculated with the trapezoidal method as the incremental area under the curve above the baseline value (iAUC). Predictors of early blood glucose response (iAUC0-3h), late blood glucose response (iAUC3-6h), total blood glucose response (iAUC0-6h), and, as indicator of time-course of the blood glucose changes, the difference between late and early response (iAUC3-6h minus 0-3h) will be evaluated using mixed-effect linear regression considering the patient's identification number (ID) as a random effect. To evaluate the significance of the random-effect factor, ANOVA will be used to test for the difference between the model with and without the random effect.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Exploring Individual Determinants of postpranDIAl Glucose Response in Type 2 diaBEteS to opTimize Therapeutic Strategies With a Personalized Approach (DIABEST)
Actual Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
May 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Men and post-menopausal women with type 2 diabetes on treatment with diet or diet plus metformin

Each participant will udergo anthropometrics and blood pressure measurements, bioimpedance analysis, indirect calorimetry, administrations of questionnaires for the evaluation of lifestyle habits, 7 days continuous glucose monitoring in parallel with diet, physical activity and sleep monitoring, and standard mixed-nutrient meals at home; a subgroup of 60 participants will undergo venous blood sampling for biochemical determinations before and after a standard mixed-nutrient meal.

Other: Test meal with postprandial samples
The mixed-nutrient test meal consists of a sandwich made with bread, spread cheese, bresaola, and one apple. Nutritional composition of the meal will be: total energy (TE) content 532 kcal, carbohydrates 68,4 g (49.3% TE), total fat 17.1 g (29.5% TE), protein 27.8 g (21.4% TE), and fibre 6 g. Before and over 4 hours after the meal, venous blood samples will be taken for biochemical evaluations at the time points -15'; 0'; 15'; 30'; 60'; 120'; 180'; 240'.

Outcome Measures

Primary Outcome Measures

  1. Post-prandial glucose response [7 days (related to the 7-day continuous glucose monitoring)]

    Post-prandial glucose response will be calculated by the trapezoidal method as the area under the curve above the baseline value (iAUC).

Secondary Outcome Measures

  1. Energy intake [7 days (related to the 7-day continuous glucose monitoring and food record)]

    The energy intake expressed in kilocalories and derived by the analysis of the 7-day food record plus the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire will be evaluated in relation to the post-prandial glucose response (iAUC).

  2. Dietary components [7 days (related to the 7-day continuous glucose monitoring and food record)]

    The dietary components, namely available carbohydrates, total proteins, animal proteins, plant proteins, total fats, saturated fats, mono- and polyunsaturated fats, fibre and sugars (all expressed in grams), will be derived by the analysis of the 7-day food record and the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, and evaluated in relation to the to the post-prandial glucose response (iAUC).

  3. Gut-microbiota composition [7 days (related to the 7-day continuous glucose monitoring)]

    Gut microbiota composition will be assessed using relative bacterial taxonomic abundances and measures of community diversity and richness (derived from 16S rRNA high-throughput sequencing of baseline stool specimens), and will be evaluated in relation to the post-prandial glucose response (iAUC).

  4. Physical activity levels [7 days (related to the 7-day continuous glucose and physical activity monitoring)]

    Physical activity levels as detected by the ActiGraph device (GT3X+ActiGraph LLC, Pensacola, FL; sampling frequency: 30 Hz) worn for 7 days on the non-dominant wrist, and expressed as % of time spent in sedentary-light-moderate activity will be evaluated in relation to the post-prandial glucose response (iAUC).

  5. Sleep duration [7 days (related to the 7-day continuous glucose and sleep monitoring)]

    Sleep metrics, namely total sleep time, sleep onset latency, wake after sleep onset (all measured in minutes), as detected by ActiGraph device worn for 7 days and nights and calculated by ActiLife software (ActiGraph LLC, Pensacola, FL; version 6.13.4), will be evaluated in relation to the post-prandial glucose response (iAUC).

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and post-menopausal women

  • HbA1c ≤ 7.5%

  • Body Mass Index (BMI) 20-39.9 kg/m2

  • Ability to comply with the study protocol activities.

Exclusion Criteria:
  • Any acute or chronic condition possibly influencing the interpretation of the results or possibly worsened because of study participation

  • Pregnancy or breast-feeding

  • Use of antibiotics, probiotics, or prebiotics during the last three months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Clinical Medicine and Surgery Federico II University Naples Italy 80131

Sponsors and Collaborators

  • Federico II University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
rivellese angela, Full Professor, Federico II University
ClinicalTrials.gov Identifier:
NCT06057246
Other Study ID Numbers:
  • 31/2023
First Posted:
Sep 28, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by rivellese angela, Full Professor, Federico II University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2023